Cullinan Therapeutics (CGEM) Projected to Post Earnings on Thursday

Cullinan Therapeutics (NASDAQ:CGEM) will likely be posting its Q3 2025 results before the market opens on Thursday, November 6th. Analysts expect Cullinan Therapeutics to post earnings of ($0.95) per share for the quarter. Individuals may visit the the company’s upcoming Q3 2025 earningresults page for the latest details on the call scheduled for Friday, November 7, 2025 at 9:30 AM ET.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings data on Thursday, August 7th. The company reported ($1.07) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.24). On average, analysts expect Cullinan Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Cullinan Therapeutics Stock Performance

NASDAQ CGEM opened at $7.69 on Thursday. Cullinan Therapeutics has a fifty-two week low of $5.68 and a fifty-two week high of $17.50. The stock has a 50 day simple moving average of $7.07 and a two-hundred day simple moving average of $7.65. The stock has a market cap of $454.25 million, a P/E ratio of -2.38 and a beta of -0.12.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Zacks Research upgraded Cullinan Therapeutics from a “strong sell” rating to a “hold” rating in a report on Tuesday, September 16th. Weiss Ratings restated a “sell (e+)” rating on shares of Cullinan Therapeutics in a research note on Wednesday, October 8th. Morgan Stanley lowered their target price on Cullinan Therapeutics from $35.00 to $28.00 and set an “overweight” rating for the company in a research note on Monday, August 18th. BTIG Research restated a “buy” rating and issued a $32.00 target price on shares of Cullinan Therapeutics in a research note on Wednesday, September 10th. Finally, HC Wainwright restated a “buy” rating and issued a $24.00 target price on shares of Cullinan Therapeutics in a research note on Friday, September 12th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Cullinan Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $26.00.

Insider Transactions at Cullinan Therapeutics

In related news, major shareholder Lynx1 Capital Management Lp acquired 626,043 shares of the stock in a transaction on Thursday, October 9th. The stock was acquired at an average price of $6.70 per share, for a total transaction of $4,194,488.10. Following the completion of the purchase, the insider owned 8,271,786 shares of the company’s stock, valued at $55,420,966.20. This represents a 8.19% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders acquired a total of 1,708,390 shares of company stock worth $11,933,684 in the last three months. 7.16% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC raised its stake in Cullinan Therapeutics by 44.6% during the second quarter. Tower Research Capital LLC TRC now owns 8,182 shares of the company’s stock valued at $62,000 after buying an additional 2,523 shares during the last quarter. Rhumbline Advisers raised its stake in Cullinan Therapeutics by 3.9% during the second quarter. Rhumbline Advisers now owns 74,105 shares of the company’s stock valued at $558,000 after buying an additional 2,767 shares during the last quarter. Invesco Ltd. raised its stake in Cullinan Therapeutics by 23.0% during the second quarter. Invesco Ltd. now owns 60,555 shares of the company’s stock valued at $456,000 after buying an additional 11,312 shares during the last quarter. Russell Investments Group Ltd. raised its stake in Cullinan Therapeutics by 39.6% during the second quarter. Russell Investments Group Ltd. now owns 40,986 shares of the company’s stock valued at $309,000 after buying an additional 11,623 shares during the last quarter. Finally, American Century Companies Inc. raised its stake in Cullinan Therapeutics by 11.1% during the second quarter. American Century Companies Inc. now owns 125,189 shares of the company’s stock valued at $943,000 after buying an additional 12,519 shares during the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics Company Profile

Cullinan Therapeutics, Inc, a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer.